Results 11 to 20 of about 1,664 (204)

Safety, Efficacy, and Patient‐Reported Outcomes From a Phase 2 Randomized Trial of Pozelimab and Cemdisiran Combination in Patients With Paroxysmal Nocturnal Hemoglobinuria [PDF]

eJHaem
Introduction Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra‐rare, life‐threatening disease associated with chronic intravascular hemolysis due to uncontrolled complement activation.
Jun‐Ho Jang, Raymond Siu Ming Wong, Christopher Hartford, Rodrigo Pavani, Lisa Aurand, Quang Nguyen, Kosalai Mohan, Karoline Meagher, Steven Sherman, Diana Rofail, Lorah Perlee, Amal Souttou, Richard J. Kelly   +12 more
doaj   +3 more sources

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial [PDF]

BMJ Open, 2023
Objectives To evaluate the 1-year efficacy and safety of once-monthly erenumab 70 mg following a 24-week double-blind treatment period (DBTP) of a phase III randomised study of Japanese patients with episodic migraine (EM) or chronic migraine (CM).Design
Koichi Hirata, Fumihiko Sakai, Miki Hasebe, Takao Takeshima, Yotaro Numachi, Ryuji Yoshida, Reija Koukakis, Daishi Yui, Gabriel Paiva da Silva Lima, Sunfa Cheng   +9 more
doaj   +2 more sources

Thespis: Causally-consistent OLTP [PDF]

Annals of computer science and information systems, 2021
Data Consistency defines the validity of a data set according to some set of rules, and different levels of data consistency have been proposed. Causal consistency is the strongest type of consistency possible when data is stored in multiple locations, and fault tolerance is desired.
Carl Camilleri, Joseph G. Vella, Vitezslav Nezval   +2 more
doaj   +4 more sources

OLTP in wonderland [PDF]

Proceedings of the Ninth International Workshop on Data Management on New Hardware, 2013
For several decades, online transaction processing has been one of the main applications that drives innovations in the data management ecosystem, and in turn the database and computer architecture communities. Despite the novel approaches from industry and various research proposals from academia, recent studies emphasize that OLTP workloads still ...
Pinar Tözün, Brian Gold, Anastasia Ailamaki   +2 more
openaire   +3 more sources

P782: A PHASE 2, RANDOMIZED TRIAL EVALUATING THE SAFETY AND EFFICACY OF POZELIMAB AND CEMDISIRAN IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA [PDF]

Hemasphere, 2023
HemaSphere, Volume 7, Issue S3, August 2023.
Jang J, Wong R, Pavani R, Aurand L, Nguyen Q, Perlee L, Souttou A, Weyne J, Kelly R.   +8 more
europepmc   +2 more sources

Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis. [PDF]

Headache, 2022
Abstract Objective To assess the long‐term efficacy and safety of erenumab in the subgroup of patients with chronic migraine (CM) in whom prior preventive treatments had failed (TF) (≥1, ≥2, and ≥3 TF medication categories) and never failed (preventive naïve or prior preventive treatments had not failed), using the data from a 52‐week, open‐label ...
Ashina M, Tepper SJ, Brandes JL, Reuter U, Boudreau GP, Weatherall M, Gantenbein AR, Doležil D, Klatt J, Wang A, Karanam AK, Cheng S, Mikol DD.   +12 more
europepmc   +2 more sources

P797: A PHASE 2, OPEN-LABEL STUDY EVALUATING THE SAFETY AND EFFICACY OF COMBINATION POZELIMAB AND CEMDISIRAN THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCH FROM ECULIZUMAB [PDF]

Hemasphere, 2023
HemaSphere, Volume 7, Issue S3, August 2023.
Kelly R, Houghton N, Munir T, Muus P, Youngs N, Aurand L, Senk B, Pavani R, Perlee L, Souttou A, Griffin M.   +10 more
europepmc   +2 more sources

Long-term safety and continued clinical benefit of erenumab 70 mg in Asian patients with chronic migraine: an open-label extension of the phase 3 DRAGON study [PDF]

The Journal of Headache and Pain
Background Erenumab is a fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor. Several double‐blind studies have demonstrated the clinical benefits of erenumab in migraine prevention. However, long-term studies on safety
Shengyuan Yu, Byung-Kun Kim, Hebo Wang, Jiying Zhou, Partha Banerjee, Jeremie Lincy, Evgeniya Reshetnyak, Zheng Li, Denise Leclair, Shuu-Jiun Wang   +9 more
doaj   +2 more sources

Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache: Final Results From a Phase 4 Randomized Placebo-Controlled Study. [PDF]

Eur J Neurol
ABSTRACT Background Erenumab‐induced medication overuse headache (MOH) remission in participants with chronic migraine (CM) in a prospective, Phase 4, randomized, placebo‐controlled trial with an open‐label treatment period (OLTP). We present 1‐year results from the combined double‐blind treatment period (DBTP) and OLTP for the stratified nonopioid ...
Tepper SJ, Dodick DW, Lanteri-Minet M, Dolezil D, Gil-Gouveia R, Lucas C, Piasecka-Stryczynska K, Szabó G, Mikol DD, Chehrenama M, Chou DE, Liu Z, da Silva Lima GP.   +12 more
europepmc   +2 more sources

Arthroscopic Bone Marrow Stimulation or Non-Operative Treatment for Osteochondral Lesions of the Tibial Plafond [PDF]

Foot & Ankle Orthopaedics, 2022
Category: Ankle; Arthroscopy Introduction/Purpose: A paucity of clinical results from osteochondral lesion of the tibial plafond (OLTP) treatment exists in the literature.
Quinten Rikken, Jari Dahmen BSc,BSc(Med), Sjoerd A. Stufkens MD, PhD, Gino Kerkhoffs MD   +3 more
doaj   +2 more sources